Aptose Biosciences (APTO) 6-K 6-K Filing for Lorus Therapeutics

Lorus Therapeutics Inc.
Consolidated Balance Sheets
	As at			As at
(amounts in 000's)	November 30, 2005			May 31, 2005
(Canadian Dollars)	(Unaudited)			(Audited)
ASSETS
Current
Cash and cash equivalents	$	10,522		$	2,776
Short-term investments		3,695			18,683
Prepaid expenses and other assets		694			1,126
		14,911			22,585
Long-term
Fixed assets		1,394			1,581
Deferred financing charges		529			568
Goodwill		606			606
Acquired patents and licenses		1,441			2,226
		3,970			4,981
	$	18,881		$	27,566
LIABILITIES
Current
Accounts payable	$	2,218		$	1,069
Accrued liabilities (note 3)		2,551			3,019
Secured convertible debentures (notes 4 and 7(b))		10,578			-
		15,347			4,088
Long-term
Secured convertible debentures		-			10,212
SHAREHOLDERS' EQUITY
Share capital (note 3)
Common shares (note 5)		144,526			144,119
Equity portion of secured convertible debentures		3,814			3,814
Stock options (note 6)		4,941			4,252
Contributed surplus		6,749			6,733
Warrants		991			991
Deficit accumulated during development stage		(157,487	)		(146,643	)
		3,534			13,266
	$	18,881		$	27,566
See accompanying notes to the unaudited consolidated interim financial statements
Basis of Presentation - Future Operations Note 1
Contingency Note 4
Subsequent Events Note 7

Lorus Therapeutics Inc.
Consolidated Statements of Loss and Deficit (unaudited)
													Period
	Three			Three			Six			Six			from inception
(amounts in 000's except for per common share data)	months ended			months ended			months ended			months ended			Sept. 5, 1986 to
(Canadian Dollars)	Nov 30, 2005			Nov 30, 2004			Nov 30, 2005			Nov 30, 2004			Nov 30, 2005
REVENUE	$	6		$	1		$	7		$	3		$	687
		6			1
EXPENSES
Cost of sales		1			1			1			1			85
Research and development (note 3)		2,631			3,838			6,588			8,887			106,826
General and administrative (note 3)		1,619			1,333			2,695			2,358			45,836
Stock-based compensation (note 6)		414			650			705			861			6,250
Depreciation and amortization		130			144			260			251			8,312
Operating expenses		4,795			5,966			10,249			12,358			167,309
Interest expense on convertible debentures		209			39			407			39			707
Accretion in carrying value of convertible debentures		180			58			366			58			792
Amortization of deferred financing charges		19			19			39			19			123
Interest income		(95	)		(136	)		(210	)		(281	)		-10,757
Loss for the period		5,102			5,945			10,844			12,190			157,487
Deficit, beginning of period		152,385			130,826			146,643			124,581			-
Deficit, end of period	$	157,487		$	136,771		$	157,487		$	136,771		$	157,487
Basic and diluted loss per common share	$	0.03		$	0.03		$	0.06		$	0.07
Weighted average number of common shares
outstanding used in the calculation of
basic and diluted loss per share		173,110			172,000			172,911			171,901
See accompanying notes to the unaudited interim consolidated financial statements

Lorus Therapeutics Inc.
Consolidated Statements of Cash Flows (unaudited)
													Period
	Three			Three			Six			Six			from inception
(amounts in 000's)	months ended			months ended			months ended			months ended			Sept. 5, 1986 to
(Canadian Dollars)	Nov 30, 2005			Nov 30, 2004			Nov 30, 2005			Nov 30, 2004			Nov 30, 2005
OPERATING ACTIVITIES
Loss for the period	$	(5,102	)	$	(5,945	)	$	(10,844	)	$	(12,190	)	$	(157,487	)
Add items not requiring a current outlay of cash:
Stock-based compensation		414			650			705			861			6,250
Interest expense on convertible debentures		209			39			407			39			707
Accretion in carrying value of convertible debentures		180			58			366			58			792
Amortization of deferred financing charges		19			19			39			19			123
Depreciation, amortization and write-down of fixed assets		522			581			1,045			1,125			19,432
Other		-			-			-			-			706
Net change in non-cash working capital
balances related to operations		1,398			(368	)		1,113			-738			3,168
Cash used in operating activities		(2,360	)		(4,966	)		(7,169	)		(10,826	)		(126,309	)
INVESTING ACTIVITIES
Maturity (purchase) of short-term investments, net		6,759			(715	)		14,988			11,527			(3,695	)
Business acquisition, net of cash received		-			-			-			-			(539	)
Acquired patents and licenses		-			-			-			-			(715	)
Additions to fixed assets		(3	)		(216	)		(73	)		(376	)		(6,047	)
Cash proceeds on sale of fixed assets		-			-			-			-			348
Cash provided by (used in)
investing activities		6,756			(931	)		14,915			11,151			(10,648	)
FINANCING ACTIVITIES
Issuance of debentures, net proceeds		-			4,400			-			4,400			12,948
Issuance of warrants		-			-			-			-			37,405
Issuance of common shares		-			106			-			111			97,371
Additions to deferred financing charges		-			(450	)		-			(450	)		(245	)
Cash provided by financing activities		-			4,056			-			4,061			147,479
Increase in cash and cash
equivalents during the period		4,396			-1,841			7,746			4,386			10,522
Cash and cash equivalents,
beginning of period		6,126			7,298			2,776			1,071			-
Cash and cash equivalents,
end of period	$	10,522		$	5,457		$	10,522		$	5,457		$	10,522
See accompanying notes to the unaudited consolidated interim financial statements